Pharma & Biotech

The Results Healthcare team is dedicated to advising large pharma corporates and smaller biotech businesses as well as companies which provide direct technical services to these companies, on bringing innovative drugs and treatments to market for the benefit of patients and society.

Our extensive international relationships in the pharma and biotech industry sets us apart from our competitors and our focus on supporting our clients in their strategic initiatives to create new business models, drive external growth and increase profitability, makes us the unrivalled advisor for the sector.

Pharma & Biotech Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has made an investment in
company name confidential
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to
Jan 2021
has divested its Ringaskiddy analytics and testing site to

Latest Insights

Insights
28th March 2022

The growing impact of Environmental, Social, and Governance (“ESG”) on pharmaceutical supply chains.

The Russian invasion of Ukraine has been touted as the final nail in the coffin of globalisation, confirming the nationalisation of key industries and products. With respect to pharmaceutical manufacturing, this is accelerating a trend which has been ongoing for 10 years, the repatriation of drug manufacturing from Asia to the US and Europe has […]

Insights
23rd February 2022

Discovery CROs: what is the “balanced business model” and how is this valued?

Discovery Contract Research Organisations (“CROs”) essentially provide lab-based discovery services such as medicinal chemistry, biological screening etc to pharma companies and biotech, and this business segment has exploded in size, sophistication and value in recent years and is now a focus of both M&A and PE investment. This is covered in our forthcoming white paper […]

Reports
1st February 2022

Pharma Commercialisation Services Update – February 2022

We are pleased to introduce you to the first of our regular sector updates on the outsourced pharma commercialisation sector.  For some time, Results Healthcare has been producing sector updates and whitepapers on the two other major areas pharmaceutical companies choose to outsource: manufacturing and research. This report focuses on commercialisation, encompassing Healthcare Marketing, Market […]